New combo therapy aims to boost survival in kids with aggressive lymphoma

NCT ID NCT02405676

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and researchers will compare their event-free survival to a previous study. The goal is to find a more effective way to control these aggressive cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rituximab (a targeted antibody) plus chemotherapy drugs (prednisone, vincristine, cyclophosphamide, cytarabine, doxorubicin, ifosfamide, etoposide, methotrexate)
What this could lead to
If successful, this could lead to a more effective treatment regimen for children with advanced B-cell lymphoma or leukemia, improving their chances of staying cancer-free.
What could go wrong
This is a Phase 2/3 trial, so results are not yet confirmed. The stronger chemotherapy may cause more side effects, and the benefit of adding rituximab is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE MATURE B-CELL NON-HODGKIN LYMPHOMA NOT OTHERWISE SPECIFIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Second University Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.